Floatz logo

cd4+cd25+ regulatory t cells

Chronic Myelogenous Leukemia

Stanford UniversityCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Monomethyl Fumarate
Center for International Blood and Marrow Transplant Research
Phase 3BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

cd4+cd25+ regulatory t cells is also rated in:

Advanced Hematologic MalignanciesDormant
CC
Indicative ·
43 / 100
View asset →
Allogeneic Hematopoietic Cell Transplantation (HCT)Dormant
CC
Indicative ·
43 / 100
View asset →
Myeloproliferative DisordersDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →